FCMV
CASI

Foresite Capital Management VI’s CASI Pharmaceuticals CASI Stock Holding History

Foresite Capital Management VI’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-979,956
Closed -$1.63M – 14
2025
Q3 		$1.63M Buy
979,956
+192,835
+24% +$344K 0.63% 12
2025
Q2 		$929K Sell
787,121
-542,262
-41% -$994K 0.52% 19
2025
Q1 		$2.87M Hold
1,329,383
– – 1.57% 13
2024
Q4 		$3.76M Buy
+1,329,383
New +$6.31M 1.68% 13

Other funds holding CASI

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Foresite Capital Management VI's CASI Position: Q4 2025 in Review

Foresite Capital Management VI sold out of CASI Pharmaceuticals (CASI) in Q4 2025, closing a stake of 979,956 shares — an estimated $1.63M sold.

Foresite Capital Management VI first reported a position in CASI in Q4 2024 and held it in 4 quarters. The position peaked at $3.76M in Q4 2024. 16 funds tracked by Wall St. Rank hold CASI as of Q4 2025.

  • Foresite Capital Management VI reported no remaining CASI Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Foresite Capital Management VI sold 979,956 CASI Pharmaceuticals shares in Q4 2025, an estimated $1.63M.
  • Foresite Capital Management VI first reported a position in CASI Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • Foresite Capital Management VI's CASI Pharmaceuticals position peaked at $3.76M in Q4 2024.
  • 16 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q4 2025.

Based on Foresite Capital Management VI's 13F filing for Q4 2025, filed 17 Feb 2026.